AGP Picks
View all

CDC advisory details risk of severe arboviral disease in patients receiving B-cell medications

The Centers for Disease Control and Prevention yesterday released a health advisory on the risk of severe arboviral disease among patients receiving B-cell-depleting or B-cell-modulating medications. Arboviruses are mostly transmitted by mosquitos and ticks. West Nile virus is the most common arbovirus. Less common arboviruses include Eastern equine encephalitis virus, Powassan virus, Jamestown Canyon virus, La Crosse virus, Cache Valley virus and Potosi virus.  
 
Examples of B-cell-depleting or B-cell-modulating medications include rituximab and biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab and ibritumomab tiuxetan. The risk of severe arboviral disease heightens from such drugs because patients may not form antibodies against a new infection. There are no approved treatments, prophylactic agents or human vaccines to prevent arboviral diseases endemic to the U.S, the CDC said. The advisory includes recommendations for health workers on treating patients with arboviral infections. 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Medicine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.